336 related articles for article (PubMed ID: 26599579)
1. Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy.
Inoue K; Takahashi T; Yamamoto Y; Suzuki E; Takahashi Y; Imai K; Inoue Y; Hirai K; Tsuji D; Itoh K
Seizure; 2015 Dec; 33():76-80. PubMed ID: 26599579
[TBL] [Abstract][Full Text] [Related]
2. Effect of CPS14217C>A genotype on valproic-acid-induced hyperammonemia.
Yagi M; Nakamura T; Okizuka Y; Oyazato Y; Kawasaki Y; Tsuneishi S; Sakaeda T; Matsuo M; Okumura K; Okamura N
Pediatr Int; 2010 Oct; 52(5):744-8. PubMed ID: 20456087
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for hyperammonemia in pediatric patients with epilepsy.
Yamamoto Y; Takahashi Y; Imai K; Mishima N; Yazawa R; Inoue K; Itoh K; Kagawa Y; Inoue Y
Epilepsia; 2013 Jun; 54(6):983-9. PubMed ID: 23409971
[TBL] [Abstract][Full Text] [Related]
4. 4217C>A polymorphism in carbamoyl-phosphate synthase 1 gene may not associate with hyperammonemia development during valproic acid-based therapy.
Inoue K; Suzuki E; Takahashi T; Yamamoto Y; Yazawa R; Takahashi Y; Imai K; Miyakawa K; Inoue Y; Tsuji D; Hayashi H; Itoh K
Epilepsy Res; 2014 Aug; 108(6):1046-51. PubMed ID: 24888247
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients.
Yamamoto Y; Takahashi Y; Suzuki E; Mishima N; Inoue K; Itoh K; Kagawa Y; Inoue Y
Epilepsy Res; 2012 Sep; 101(3):202-9. PubMed ID: 22542569
[TBL] [Abstract][Full Text] [Related]
6. Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy.
Tseng YL; Huang CR; Lin CH; Lu YT; Lu CH; Chen NC; Chang CC; Chang WN; Chuang YC
Medicine (Baltimore); 2014 Sep; 93(11):e66. PubMed ID: 25192484
[TBL] [Abstract][Full Text] [Related]
7. CPS1 T1405N polymorphism, HDL cholesterol, homocysteine and renal function are risk factors of VPA induced hyperammonemia among epilepsy patients.
Chen L; Tian Q; Zhang M; Chen D; Gao X; Yang H; Li H; Li C; Wen J; Li Y; Tian X; Chen P
Epilepsy Res; 2019 Aug; 154():139-143. PubMed ID: 31151073
[TBL] [Abstract][Full Text] [Related]
8. Risk factors of hyperammonemia in epilepsy patients with valproic acid therapy.
Kwack DW; Kim DW
Clin Neurol Neurosurg; 2023 Oct; 233():107962. PubMed ID: 37717359
[TBL] [Abstract][Full Text] [Related]
9. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.
Hamed SA; Abdella MM
Epilepsy Res; 2009 Sep; 86(1):32-41. PubMed ID: 19446440
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy.
Zhu X; Li X; Zhang T; Zhao L
Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):628-634. PubMed ID: 29791065
[TBL] [Abstract][Full Text] [Related]
11. Changing incidence of hyperammonemia in Japan from 2006 to 2013: expansion of new antiepileptic drugs reduces the risk of hyperammonemia.
Yamamoto Y; Takahashi Y; Imai K; Mishima N; Kagawa Y; Inoue Y
Eur J Clin Pharmacol; 2015 Dec; 71(12):1517-24. PubMed ID: 26391520
[TBL] [Abstract][Full Text] [Related]
12. [Hyperammonemia in valproate therapy in children and adolescents].
Laub MC
Nervenarzt; 1986 May; 57(5):314-8. PubMed ID: 3088461
[TBL] [Abstract][Full Text] [Related]
13. Hyperammonemia following intravenous valproate loading.
DeWolfe JL; Knowlton RC; Beasley MT; Cofield S; Faught E; Limdi NA
Epilepsy Res; 2009 Jul; 85(1):65-71. PubMed ID: 19299111
[TBL] [Abstract][Full Text] [Related]
14. Differential ammonia decay kinetics indicates more than one concurrent etiological mechanism for symptomatic hyperammonemia caused by valproate overdose.
Mojumder DK; De Oleo RR
Indian J Pharmacol; 2014; 46(3):345-7. PubMed ID: 24987188
[TBL] [Abstract][Full Text] [Related]
15. Potential relationships between transaminase abnormality and valproic acid clearance or serum carnitine concentrations in Japanese epileptic patients.
Goto S; Seo T; Hagiwara T; Ueda K; Yamauchi T; Nagata S; Ando Y; Ishitsu T; Nakagawa K
J Pharm Pharmacol; 2008 Feb; 60(2):267-72. PubMed ID: 18237476
[TBL] [Abstract][Full Text] [Related]
16. Valproic acid-induced hyperammonemia and thrombocytopenia in an elderly woman.
Mallet L; Babin S; Morais JA
Ann Pharmacother; 2004 Oct; 38(10):1643-7. PubMed ID: 15316109
[TBL] [Abstract][Full Text] [Related]
17. Gait instability in valproate-treated patients: Call to measure ammonia levels.
Kipervasser S; Elger CE; Korczyn AD; Nass RD; Quesada CM; Neufeld MY
Acta Neurol Scand; 2017 Nov; 136(5):401-406. PubMed ID: 28436001
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of the effect of long term valproic acid treatment on plasma levels of carnitine, ammonia and amino acids related to the urea cycle in pediatric epileptic patients].
Navarro-Quesada FJ; Lluch-Fernández MD; Vaquero-Abellán M; Marchante-Serrano C; Jiménez C
Rev Neurol; 1997 Jul; 25(143):1037-44. PubMed ID: 9280630
[TBL] [Abstract][Full Text] [Related]
19. Valproate-induced hyperammonemia.
Batshaw ML; Brusilow SW
Ann Neurol; 1982 Mar; 11(3):319-21. PubMed ID: 6807193
[TBL] [Abstract][Full Text] [Related]
20. Valproate induced non hepatic hyperammonaemic encephalopathy (VNHE)--a study from tertiary care referral university hospital, north India.
Mehndiratta MM; Mehndiratta P; Phul P; Garg S
J Pak Med Assoc; 2008 Nov; 58(11):627-31. PubMed ID: 19024136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
